Ongoing MDS Studies in Italy

ESH eLearning, Valeria Santini, 366504

Introduction

ESH eLearning, Raphael Itzykson, 366503

Discussion

ESH eLearning, Faculty / Presenters, 366502

Keynote lecture : routine integration of molecular data in the prognostic stratification: the IPSS molecular

ESH eLearning, Elsa Bernard, 366501

Panel discussion

ESH eLearning, Faculty / Presenters, 366500

Novel strategies to treat cytopenia in low risk MDS

ESH eLearning, Uwe Platzbecker, 366499

A renewed role for intensive chemotherapy ?

ESH eLearning, Thomas Cluzeau, 366498

Higher risk MDS: lessons from elderly AML

ESH eLearning, Lionel ADES, 366497

Strategies to improve HMA based therapy

ESH eLearning, Pierre Fenaux, 366496

Panel discussion

ESH eLearning, Faculty / Presenters, 366495

Overview of novel therapeutics in MDS: lessons from the lab

ESH eLearning, Valeria Santini, 366494

Current treatment guidelines for CMML and rare subtypes

ESH eLearning, Raphael Itzykson, 366493

Allo transplantation: when and how?

ESH eLearning, Marie Robin, 366492

HMAs: when and how

ESH eLearning, Mikkael A. Sekeres, 366491

Panel discussion

ESH eLearning, Faculty / Presenters, 366490

How to best define del (5q)

ESH eLearning, María Díez Campelo, 366489

Why and how should we target mature cells of the clone in chronic myelomonocytic leukemia

ESH eLearning, Eric Solary, 366488

Panel discussion

ESH eLearning, Faculty / Presenters, 366487

Treatment Patterns and Overall Survival in Patients with Intermediate-Risk Myelodysplastic Syndrome (MDS): A Retrospective Analysis from the Grupo Español De Síndromes Mielodisplásicos (GESMD) Spanish MDS Registry

ESH eLearning, María Díez Campelo, 366486

The best soup has many ingredients: prognosis in MDS combining clinical and biologic information

ESH eLearning, Jaroslaw Maciejewski, 366485

The best clinical prognostic system for MDS is…

ESH eLearning, Rami S. Komrokji, 366484

The basics are not enough: how molecular genetics make the difference of MDS

ESH eLearning, Torsten Haferlach, 366483

Panel discussion

ESH eLearning, Faculty / Presenters, 366482

Artificial intelligence for treatment and prognosis

ESH eLearning, Anne Sophie Kubasch, 366481

Panel discussion

ESH eLearning, Faculty / Presenters, 366480

The case of iron

ESH eLearning, Valeria Santini, 366479

Impact of the microbiome on hematopoiesis

ESH eLearning, Katherine King, 366478

The immunome

ESH eLearning, Shahram KORDASTI, 366477

Panel discussion

ESH eLearning, Faculty / Presenters, 366476

Clonal Cytopenia of Undetermined Significance

ESH eLearning, Luca Malcovati, 366475

CHIP: Clonal hematopoiesis of not-so-indeterminate potential

ESH eLearning, Klaus Metzeler, 366474

Panel discussion

ESH eLearning, Faculty / Presenters, 366473

Brief oral communication

ESH eLearning, Vi Lam, 366472

CAR-T cell therapy in CLL

ESH eLearning, Tanya Siddiqi, 366471

MAPK/ERK

ESH eLearning, Jennifer R. Brown, 366470

Panel discussion

ESH eLearning, Faculty / Presenters, 366469

Brief oral communication

ESH eLearning, Arnon Kater, 366468

CAR-T cell immunotherapy for CLL: a chance for cure in the era of small molecules?

ESH eLearning, Marco Ruella, 366467

Future of PI3Ks

ESH eLearning, John Gribben, 366466

Panel discussion

ESH eLearning, Faculty / Presenters, 366465

Brief oral communication

ESH eLearning, Kristyna Zavacka, 366464

Non-covalent BTK inhibitors (ARQ531 / MK1026; pirtobrutinib)

ESH eLearning, Anthony Mato, 366463

Resistance to covalent BTK inhibitors

ESH eLearning, Adrian Wiestner, 366462

Panel discussion

ESH eLearning, Faculty / Presenters, 366461

Zanubrutinib and combinations

ESH eLearning, Alessandra Tedeschi, 366460

Acalabrutinib and combinations

ESH eLearning, Richard Furman, 366459

Panel discussion

ESH eLearning, Faculty / Presenters, 366458

Brief oral communication

ESH eLearning, Fabrizio Mavilia, 366457

Defined duration vs MRD driven time-limited therapy

ESH eLearning, Talha Munir, 366456

BTK – BCL-2 combinations

ESH eLearning, John Allan, 366455

Venetoclax antibody combinations

ESH eLearning, Othman Al-Sawaf, 366454

Panel discussion

ESH eLearning, Faculty / Presenters, 366453

Brief oral communication

ESH eLearning, Emma Kennedy, 366452

Reversed microenvironmental stimuli; how CLL cells suppress T cell function

ESH eLearning, Arnon Kater, 366451

Effects of CXCR4- and macrophage-derived signals on the survival and growth of CLL cells

ESH eLearning, Dimitar Efremov, 366449

CD49d: a biologically relevant molecule and important prognostic marker in CLL

ESH eLearning, Chris Pepper, 366448

Panel discussion

ESH eLearning, Faculty / Presenters, 366447

Brief oral communication

ESH eLearning, Anna Andrzejczak, 366446

Prognostic role of rare gene mutations

ESH eLearning, Davide Rossi, 366445

IG mutational status and gene mutations

ESH eLearning, Richard Rosenquist Brandell, 366444

Panel discussion

ESH eLearning, Faculty / Presenters, 366443

Brief oral communication

ESH eLearning, Selena Mimmi, 366442

How do we look at MRD in 2021

ESH eLearning, Andrew Rawstron, 366441

Complex karyotype: what is relevant?

ESH eLearning, Panagiotis Baliakas, 366440

Low level TP53 clones: what is the significance?

ESH eLearning, Sarka Pospisilova, 366439

Panel discussion

ESH eLearning, Faculty / Presenters, 366438

Richter’s transformation

ESH eLearning, Silvia Deaglio, 366436

What is the definition of high risk CLL now?

ESH eLearning, Kostas Stamatopoulos, 366435

MBL; low vs high count

ESH eLearning, Alberto Orfao, 366434

Panel discussion

ESH eLearning, Faculty / Presenters, 366263

Brief Oral Communication: Efficacy and Safety of Sabatolimab (MBG453) in Combination with Hypomethylating Agents (HMAs) in Patients (Pts) with Very High/High-Risk Myelodysplastic Syndrome (vHR/HR-MDS) and Acute Myeloid Leukaemia (AML): Final Analysis from a Phase Ib Study

ESH eLearning, Andrew Brunner, 366262

Interactive case: Combining checkpoints inhibitors

ESH eLearning, Patrick A. Patrick A. Brown, 366261

Case-based lecture: New developments in CAR-T and NK cell therapy

ESH eLearning, Fabio Ciceri, 366260

Discussion

ESH eLearning, Faculty / Presenters, 366258

CAR T-cell as a bridge to transplant

ESH eLearning, Claire Roddie, 366257

CAR T-cell is a curative ALL therapy

ESH eLearning, Shannon Maude, 366256

Introduction

ESH eLearning, Hervé Dombret, 366255

Discussion

ESH eLearning, Faculty / Presenters, 366254

Post-remission and maintenance treatment for non-transplanted patients

ESH eLearning, Nicholas Short, 366253

Which patients with Ph+ ALL should be transplanted?

ESH eLearning, Sabina Chiaretti, 366252

Initial treatment for Ph+ ALL chemo free or not

ESH eLearning, Yves Chalandon, 366251

Introduction

ESH eLearning, Nicola GÖKBUGET, 366250

Panel discussion

ESH eLearning, Faculty / Presenters, 366249

Brief Oral Communication: AGILE: A Global, Randomized, Double-Blind, Phase 3 Study of Ivosidenib + Azacitidine Versus Placebo + Azacitidine in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 Mutation

ESH eLearning, Christian Récher, 366248

Interactive case: The future of IDH inhibitors

ESH eLearning, Eytan Stein, 366247

Case-based lecture: Innovative treatment for relapsed AML

ESH eLearning, Jorge Sierra, 366246

Case-based lecture: Maintenance therapy without transplant

ESH eLearning, Gail Roboz, 366245

Case-based lecture: How to treat FLT3 mutant AML at diagnosis and at relapse?

ESH eLearning, Alexander Perl, 366244

Panel discussion

ESH eLearning, Faculty / Presenters, 366269

Interactive case: The future of menin inhibitors

ESH eLearning, Eunice Wang, 366243

Brief Oral Communication: A Phase Ib Study Exploring MDM2 Inhibitor Siremadlin (HDM201) in Combination with Venetoclax in Patients with Acute Myeloid Leukemia or Very High/High-Risk Myelodysplastic Syndrome

ESH eLearning, Kimmo Porkka, 366268

Case-based lecture: Which AML patients should be transplanted in CR1

ESH eLearning, Raphael Itzykson, 366267

Case-based lecture: Post-transplant maintenance therapies

ESH eLearning, Rita Assi, 366265

Interactive case: Is there a place for transplantation in AML patients not intensively treated frontline?

ESH eLearning, Pierre Fenaux, 366264

Discussion

ESH eLearning, Faculty / Presenters, 366242

The value of pre-transplant MRD in ALL and how to use it?

ESH eLearning, Sebastian Giebel, 366241

The value of pre-transplant MRD in AML and how to use it?

ESH eLearning, Roland B. Walter, 366240

Introduction

ESH eLearning, Charles Craddock, 366239

Discussion

ESH eLearning, Faculty / Presenters, 366238

CON: The reasons to favour venetoclax-azaitidine

ESH eLearning, Courtney DiNardo, 366237